Results 101 to 110 of about 53,892 (275)

Estimating the prevalence of hematological malignancies and precursor conditions using data from Haematological Malignancy Research Network (HMRN) [PDF]

, 2016
Objective: Well-established cancer registries that routinely link to death registrations can estimate prevalence directly by counting patients alive at a particular point in time (observed prevalence).
Crouch, Simon, Li, Jinlei, Oliver, Steven Edward, Roman, Eve, Smith, Alexandra Gwen   +4 more
core   +1 more source

A Transcriptional Map of Human Tonsil Architecture: Beyond the Sum of (Single Cell) Parts

European Journal of Immunology, Volume 56, Issue 1, January 2026.
Picture‐book compartmentalization makes tonsillar tissue an ideal model to study spatial immunology. Using single‐molecule imaging (SMI) of whole‐tissue sections, we showcase many an alternative view on tissue composition and architecture that these data and concomitant analyses provide—at the level of single cells, cellular neighborhoods, and ...
Helena L. Crowell, Laura Llaó‐Cid, Gerard Frigola, Samuel Gunz, Irene Ruano, Patricia Lorden, Max Ruiz, Marta Kulis, José Ignacio Martin‐Subero, Holger Heyn, Elias Campo, Anna Pascual‐Reguant   +11 more
wiley   +1 more source

The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index

Haematologica, 2012
Background Mantle cell lymphoma is a clinically heterogeneous disease characterized by overexpression of cyclin D1 protein. Blastoid morphology, high proliferation, and secondary genetic aberrations are markers of aggressive behavior.
Julia Slotta-Huspenina, Ina Koch, Laurence de Leval, Gisela Keller, Margit Klier, Karin Bink, Marcus Kremer, Mark Raffeld, Falko Fend, Leticia Quintanilla-Martinez   +9 more
doaj   +1 more source

Guess what: Chronic 13q14.3+/CD5‐ /CD23+ lymphocytic leukemia in blood and t(11;14)(q13;q32)+/CD5+/CD23‐ mantle cell lymphoma in lymph nodes! [PDF]

, 2003
Cytometry B Clin Cytom. 2003 Jan;51(1):41-4. Guess what: Chronic 13q14.3+/CD5-/CD23+ lymphocytic leukemia in blood and t(11;14)(q13;q32)+/CD5+/CD23- mantle cell lymphoma in lymph nodes!
BROCHADO, P., CABEDA, J.M., CANELHAS, A., DOS ANJOS TEIXEIRA, M., FONSECA, S., JUSTICA, B., LIMA, M., MOTA, A., PINTO, L., QUEIROS, M.L., SANTOS, A.H., SILVA, C.   +11 more
core   +1 more source

Composite Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Diagnostic and Therapeutic Challenge

eJHaem, Volume 7, Issue 1, February 2026.
Matthew T. Ye, Yaling Yang, M. James You
wiley   +1 more source

Nanomedicine for the Treatment of Non-Hodgkin Lymphoma [PDF]

, 2019
Non-Hodgkin lymphoma, or NHL, is the predominant category of lymphoma. NHL is a type of lymphoid hematopoietic malignancy which approximately 70,000 Americans are diagnosed with annually, with the number of diagnoses growing annually.
Gandhi, B.Pharm, Tanvi
core   +1 more source

Biological heterogeneity in adult IRF4‐rearranged large B‐cell lymphoma: Stratification by age and anatomical site

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Large B‐cell lymphoma (LBCL) with IRF4 rearrangement (LBCL‐IRF4‐R) is a rare subtype predominantly diagnosed in children and young adults. Whether adult LBCL cases with IRF4 rearrangement (IRF4‐R) should be classified as LBCL‐IRF4‐R remains unclear. Clinicopathological and molecular features of 61 adult LBCL cases with IRF4‐R were analyzed and
Yuxiu Zhang, Anqi Li, Yimin Li, Xuan Wang, Lei Dong, Lei Zhang, Pengpeng Xu, Yue Wang, Xia Shen, Haimin Xu, Binshen Ouyang, Chaofu Wang, Hongmei Yi   +12 more
wiley   +1 more source

Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW. [PDF]

, 2017
Purpose: B-cell lymphomas must acquire resistance to apoptosis during their development. We recently discovered BCLW, an antiapoptotic BCL2 family member thought only to contribute to spermatogenesis, was overexpressed in diffuse large B-cell lymphoma ...
Adams, Clare M., Eischen, Christine M., Gong, MD, Jerald Z., Mitra, Ramkrishna   +3 more
core   +1 more source

Impact of novel therapies for mantle cell lymphoma in the real world setting : a report from the UK's Haematological Malignancy Research Network (HMRN) [PDF]

, 2018
The treatment landscape for mantle cell lymphoma (MCL) has changed dramatically in recent years, with findings from clinical trials reporting improvements in survival. Data on the general patient population are, however, sparse; and it is unclear whether
Abrahamsson, Abrahamsson, Andersen, Atilla, Chandran, Colbourn, Dreyling, Dreyling, Dreyling, Epperla, Furtado, Gouill, Harris, Herrmann, Hill, Hoster, Hoster, Kahl, Klapper, Kluin-Nelemans, Kuittinen, Kurnaz, Leonard, Leux, Marcos-Gragera, Martin, Martin, Martin, McKay, Rule, Rule, Rummel, Rummel, Sawalha, Schulz, Smith, Smith, Swerdlow, Vergote, Vidal, Wang, Zaja   +41 more
core   +1 more source

Managing Treatment‐Emergent Immune Effector Cell‐Associated Hemophagocytic Lymphohistiocytosis‐Like Syndrome Following CAR‐T Cell Therapy: A Case‐Based Review of the use of Emapalumab

Hematological Oncology, Volume 44, Issue 1, January 2026.
ABSTRACT Chimeric antigen receptor T (CAR‐T) cell therapies have revolutionized the treatment of hematological malignancies, achieving high response rates in patients with relapsed or refractory disease. Despite these benefits, CAR‐T cell therapies are associated with unique toxicities, including cytokine release syndrome (CRS), immune effector cell ...
Livia Donzelli, Veronica Zullino, Giovanni Fernando Torelli, Maria Stefania De Propris, Mario Piazzolla, Franco Ruberto, Maurizio Martelli, Alice Di Rocco   +7 more
wiley   +1 more source